Free Trial
One Day Left! MarketBeat All Access Returns to $249 Soon
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion
NASDAQ:KOD

Kodiak Sciences (KOD) Stock Price, News & Analysis

Kodiak Sciences logo
$99.40 +2.36 (+2.43%)
As of 09:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Kodiak Sciences Stock (NASDAQ:KOD)

Advanced

Key Stats

Today's Range
$97.00
▼
$97.00
50-Day Range
$31.52
▼
$99.87
52-Week Range
$15.83
▼
$104.00
Volume
1,168 shs
Average Volume
1.13 million shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.71
Consensus Rating
Moderate Buy

Company Overview

Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye. Its lead investigational program, tarcocimab tedromer (KSI-301), is an anti-vascular endothelial growth factor therapy developed for several retinal vascular diseases. Kodiak has also investigated additional ophthalmic candidates and combination approaches using the platform.

Founded in 2015 and headquartered in Palo Alto, California, Kodiak has conducted clinical development activities in the United States and international markets. The company’s therapies remain investigational, and its business is centered on research and clinical development rather than commercial products. Victor Perlroth, M.D., is the company’s co-founder and chief executive officer.

AI Generated. May Contain Errors.

Kodiak Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

KOD MarketRank™: 
2.477390180875 of 5 stars

Kodiak Sciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 448th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Kodiak Sciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Kodiak Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Kodiak Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.97) to ($4.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kodiak Sciences is -23.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kodiak Sciences is -23.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kodiak Sciences has a P/B Ratio of 32.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Kodiak Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    24.33% of the float of Kodiak Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kodiak Sciences has a short interest ratio ("days to cover") of 4.24.
  • Change versus previous month

    Short interest in Kodiak Sciences has recently decreased by 9.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kodiak Sciences does not currently pay a dividend.

  • Dividend Growth

    Kodiak Sciences does not have a long track record of dividend growth.

  • News Sentiment

    Kodiak Sciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Kodiak Sciences this week, compared to 5 articles on an average week.
  • Search Interest

    Only 11 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $156,986,026.00 in company stock, which represents 2.5740% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Kodiak Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $156,986,026.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    44.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kodiak Sciences' insider trading history.
Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KOD Stock News Headlines

Kodiak Sciences Inc. (KOD)
$29.97 or $0 today
The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.tc pixel
See More Headlines

KOD Stock Analysis - Frequently Asked Questions

Kodiak Sciences' stock was trading at $27.96 on January 1st, 2026. Since then, KOD shares have increased by 247.1% and is now trading at $97.04.

Kodiak Sciences Inc. (NASDAQ:KOD) released its quarterly earnings results on Thursday, August, 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $0.09.

Kodiak Sciences (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

Kodiak Sciences' top institutional shareholders include State of Wyoming (0.02%), China Universal Asset Management Co. Ltd., VIRGINIA RETIREMENT SYSTEMS ET Al (0.01%) and Abel Hall LLC (0.01%). Insiders that own company stock include Bros Advisors Lp Baker and John A Borgeson.
View institutional ownership trends
.

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Marvell Technology (MRVL) and Rocket Lab (RKLB).

Company Calendar

Last Earnings
8/13/2026
Today
10/29/2026
Next Earnings (Estimated)
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KOD
CIK
1468748
Fax
N/A
Employees
124
Year Founded
2009

Price Target and Rating

High Price Target
$145.00
Low Price Target
$61.00
Potential Upside/Downside
+5.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$229.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-273.23%
Return on Assets
-85.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.49
Quick Ratio
2.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.97 per share
Price / Book
33.47

Miscellaneous

Outstanding Shares
62,850,000
Free Float
34,944,000
Market Cap
$6.25 billion
Optionable
Optionable
Beta
2.03

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:KOD) was last updated on 10/29/2026 by MarketBeat.com Staff.
From Our Partners